Cardinal Health (CAH) reported $55.26 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 3.8%. EPS of $1.93 for the same period compares to $1.82 a year ago.
The reported revenue represents a surprise of +0.69% over the Zacks Consensus Estimate of $54.89 billion. With the consensus EPS estimate being $1.75, the EPS surprise was +10.29%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Cardinal performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Pharmaceutical and Specialty Solutions: $50.85 billion compared to the $50.76 billion average estimate based on four analysts. The reported number represents a change of -4.4% year over year.
- Revenue- Other: $1.28 billion compared to the $1.23 billion average estimate based on four analysts.
- Revenue- Medical Products and Distribution: $3.15 billion versus the four-analyst average estimate of $3.18 billion. The reported number represents a year-over-year change of -0.4%.
- Segment profit- Pharmaceutical and Specialty Solutions: $531 million compared to the $496.49 million average estimate based on four analysts.
- Segment profit- Other: $118 million compared to the $110.67 million average estimate based on four analysts.
- Segment profit- Global Medical Products and Distribution: $18 million compared to the $25.77 million average estimate based on four analysts.
Shares of Cardinal have returned +8% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
